New chemo drug shows promise for tough testicular cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 15 years or older * Evidence of advanced NSGCT documented either by pathology or by elevated tumor markers (AFP or hCG) and a compatible clinical presentation * Primary site located in either the testis, the retroperitoneum or the mediastinum * Progressive disease after at least 2 lines of chemotherapy for advanced NSGCT (ie, non-stage I) * In case of brain metastases, confirm that patients should be stable / controlled with corticosteroid/anti seizures agents * No other progressive carcinoma within previous the 5 years, except for basal-cell carcinoma of the skin * Life expectancy \>/= 3 months * Adequate hematologic function : * Hemoglobin \>/= 10.0 g/dL * Absolute neutrophil count \>/= 1.5 x 10 \^ 9/L, * Platelet count \>/= 100 x 10 \^ 9/L, * Adequate organ function * Serum creatinine \< 1.5 x ULN. If serum creatinine 1.0 - 1.5 x ULN, creatinine clearance calculated (or measured) according to CKD-EPI formula (see Appendix B) \> 60 mL/min * AST/SGOT and ALT/SGPT \</= 1.5 x ULN * Bilirubin \</= 1.5 x ULN * Information delivered to patient and informed consent form signed by the patient or his legal representative * Patient affiliated to a social security system or beneficiary of the same Exclusion Criteria: * Patients receiving anti cancer therapy within 4 weeks prior to enrolment * Previous radiotherapy within 4 weeks prior to enrolment * Serious uncontrolled concurrent medical illness * History of severe hypersensitivity reaction (\>/= grade 3) to polysorbate 80 containing drugs or to other taxanes * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (see Appendix A). A one week wash-out period is necessary for patients who are already on these treatments. * Patient with reproductive potential not implementing accepted and effective method of contraception for up to 6 months after the last dose of cabazitaxel. * Active Grade \>/= 3 peripheral neuropathy * Patients who have had a major surgery within 4 last weeks prior enrolment * Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed